BioCentury
ARTICLE | Clinical News

Eiger completes enrollment in Phase II to treat PAH

May 19, 2017 7:10 PM UTC

Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR) completed enrollment of 61 patients with pulmonary arterial hypertension (PAH) in the North American Phase II LIBERTY trial evaluating Bestatin ubenimex plus standard of care (SOC). Patients in the double-blind, placebo-controlled trial will receive thrice-daily 150 mg oral Bestatin for 24 weeks.

Eiger expects data from LIBERTY in 1Q18...